| Kumpaitiene et al.[24], 2018 |
Prospective observational study |
59/0 |
Erythromycin (rSO2, NSE and GFAP) |
22 (37) on POD10 |
No significant changes in blood GFAP level occurred in any patients; decreased rSO2 and increased NSE level did not correlate with rate of POCD |
Erythromycin |
|
| Thomaidou et al.[25], 2017 |
Prospective randomized pilot study |
40/0 |
Erythromycin (25 mg/kg) vs. control (Serum IL-1, IL-6 and tau) |
19 (47.4) vs. 16 (76.2) just after hospital discharge, and 6 (31.6) vs. 38 (95.2) in 3 months |
|
Erythromycin |
|
| Kok et al.[26], 2017 |
Randomized clinical trial |
57 (CABG or OPCAB) |
(Serum brain fatty acid-binding protein) |
15 (26) in 3 months, and 13 (27) in 15 months |
Classical neuronal injury-related biomarkers had no prognostic value for POCD |
|
|
| Silva et al.[27], 2016 |
Prospective observational study |
88/0 |
(Serum S100β and NSE) |
23 (26.1) at 21 days, and 20 (22.7) in 6 months |
Serum S100B was more accurate than NSE in the detection of POCD |
|
|
| ÖztÜrk et al.[28], 2016 |
Prospective, randomized, double-blind study |
40/0 |
Pulsatile vs. nonpulsatile flow (Serum 100β and NSE) |
3 (15) vs. 3 (15) on POD3 |
No difference between types of pump flow for POCD |
|
|
| Oldham et al.[29], 2015 |
Prospective observational cohort study |
102/0 |
|
14 (14) on POD2 through discharge |
Cognitive and functional impairment independently predicted postoperative delirium and delirium severity |
|
Preoperative cognitive and functional impairment |
| Hassani et al.[30], 2015 |
Randomized, double-blind, placebo-controlled trial |
61/0 |
Valerian capsule (containing 530 mg of valerian root extract/capsule) (1,060 mg/day) vs. placebo capsule each 12 h for 8 weeks |
Valerian prophylaxis: reduced odds of POCD in comparison to placebo on POD10 and in 2 months |
|
Valerian capsule |
|
| Dong et al.[31], 2014 |
Prospective cohort study |
108/0 |
(Plasma copeptin) |
35 (32.4) on POD7 |
Postoperative plasma copeptin level may be a useful predictor of POCD |
|
|
| Trubnikova et al.[32], 2014 |
Case-control study |
101/0 |
MCI vs. non-MCI |
36 (72) vs. 40 (79) at early stage (P=0.5), and 36 (72) vs. 35 (70) in 1 year (P=0.8) |
MCI was not a leading cause of early or long-term POCD |
|
|
| Kok et al.[33], 2014 |
Randomized pilot study |
29/30 |
CABG vs. OPCAB (Cerebral oximetry variable) |
11 (39) vs. 4 (14) at early stage (P=0.50), and 4 (14) vs. 0 (0) at 3 months (P=0.03) |
There was no association between intraoperative cerebral oximetry variables and POCD at any stage |
OPCAB |
CABG |
| Szwed et al.[34], 2014 |
Prospective observational single-surgeon trial |
0/74 |
"No-touch" OPCAB vs. "traditional" OPCAB |
10 (28.6) vs. 20 (51.3) on POD7 (discharge) |
|
"No touch" OPCAB |
|
| Fontes et al.[35], 2014 |
Retrospective study |
118/0 (CABG or CABG + valve surgery with CPB) |
Arterial hyperoxia during CPB |
53 (45) at 6 weeks |
Arterial hyperoxia during CPB was not associated with neurocognitive decline after 6 weeks |
|
|
| Sirvinskas et al.[36], 2014 |
Prospective study |
50/0 |
Head-cooling vs. no head-cooling |
9 (36) vs. 16 (64) on POD10 (P=0.048) |
|
Head-cooling technique during the aortic cross-clamp |
|
| Joung et al.[37], 2013 |
Randomized pilot study |
0/70 |
rIPC vs. control |
10 (28.6) vs. 11 (31.4) on POD7 (P=0.794) |
rIPC did not reduce the incidence of POCD |
|
|
| Mu et al.[38], 2013 |
Prospective cohort study |
166/0 |
(Serum cortisol) |
66 (39.8) on POD7 |
|
|
High serum cortisol level on POD1 |
| Kadoi et al.[39], 2011 |
Prospective study |
124/0 |
Normal vs. medium vs. impaired cerebrovascular CO2 reactivity |
20 (30) vs. 10 (25) vs. 11 (57) on POD7, and 16 (24) vs. 9 (23) vs. 5 (26) at 6 months |
|
|
Impaired cerebrovascular CO2 reactivity |
| de Tournay-Jettéet al.[40], 2011 |
Prospective study |
61 (CABG or OPCAB) |
(rSO2) |
46 (80.7) on POD4-7, and 23 (38.3) in 1 month |
|
|
Intraoperative rSO2 desaturation |
| Slater et al.[41], 2009 |
Prospective controlled study |
240/0 |
(rSO2 saturation) |
70 (29) in 3 months |
Patients with rSO2 desaturation score >3,000%-second had a significantly higher risk of POCD |
|
rSO2 desaturation score >3,000%-second |
| Haljan et al.[42], 2009 |
Prospective study |
32/0 |
Erythropoietin vs. placebo |
2 (8.3) vs. 3 (38) in 2 months (P=0.085) |
|
Erythropoietin |
|
| Silbert et al.[43], 2008 |
Prospective study |
282/0 |
(Apolipoprotein genotype) |
33 (12) in 3 months, and 31 (11) in 12 months |
There was no relationship between presence of the apolipoprotein epsilon4 allele or any of the six genotypes and POCD |
|
|
| Jensen et al.[44], 2008 |
Prospective randomized study |
47/43 |
CABG vs. OPCAB |
4 (9) vs. 8 (19) in 12 months (P=0.18) |
No significant differences in the incidence of POCD between CABG and OPCAB group |
|
|
| Hogue et al.[45], 2008 |
Prospective study |
113/0 (CABG/CABG+ valve operation) |
(Apolipoprotein epsilon4 genotype) |
28 (25) in 4-6 weeks |
Mild atherosclerosis of the ascending aorta, CPB time, aortic cross-clamping time and length of hospitalization, but not apolipoprotein epsilon4 genotype were risks for POCD |
|
|
| Puskas et al.[46], 2007 |
Prospective study |
525/0 |
Hyperglycemic vs. nonhyperglycemic |
157 (40) vs. 38 (29) at 6 weeks (P=0.017) |
|
|
Intraoperative hyperglycemia |
| Kadoi and Goto[47], 2007 |
Prospective study |
106/0 |
Sevoflurane vs. non-sevoflurane |
13 (22) vs. 11 (23) in 6 months |
Sevoflurane did not have any significant effects on POCD |
|
|
| Kadoi and Goto[48], 2006 |
Prospective study |
88/0 |
|
24 (27.3) in 6 months |
Age, diabetes mellitus and renal failure were associated with POCD at 6 months |
|
|
| Jensen et al.[49], 2006 |
Prospective randomized study |
51/54 |
OPCAB vs. CABG |
4 (7.4) vs. 5 (9.8) in 3 months (P=0.7) |
No significant difference in the incidence of POCD between OPCAB and CABG |
|
|
| Silbert et al.[50], 2006 |
Prospective randomized study |
326/0 |
High-dose fentanyl vs. low-dose fentanyl |
22 (13.7) vs. 40 (23.6) in 1 week (P=0.03) |
|
High-dose fentanyl |
Low-dose fentanyl |
| Wang et al.[51], 2002 |
Prospective randomized study |
88/0 |
Lidocaine vs. placebo |
8 (18.6) vs. 18 (40.0) at early stage (?) (P=0.028) |
|
Intraoperative administration of lidocaine |
|